Obviousness

Obviousness Analysis of US Patent 11058757 Under 35 U.S.C. § 103

This analysis identifies combinations of prior art references that would render the claims of US patent 11058757 obvious to a person having ordinary skill in the art (PHOSITA). The patent, titled "Saccharide-polypeptide conjugate compositions and methods of use thereof," generally covers multi-component pneumococcal conjugate vaccines. The critical aspects of the independent claims revolve around a pharmaceutical composition comprising at least five distinct saccharide-polypeptide conjugate components from different Streptococcus pneumoniae serotypes, methods of use, and manufacturing processes.

Understanding the Person Having Ordinary Skill in the Art (PHOSITA)

A PHOSITA in the field of pneumococcal conjugate vaccines would possess knowledge of microbiology, immunology, biochemistry, and pharmaceutical formulation. This includes understanding the principles of antigen presentation, immunogenicity of saccharides and proteins, methods for conjugating saccharides to carrier proteins, and the development of multi-valent vaccines to target various serotypes of a pathogen like Streptococcus pneumoniae. They would also be aware of the existing pneumococcal vaccines, such as the polysaccharide vaccines (e.g., PPSV23) and earlier conjugate vaccines (e.g., PCV7, PCV13).

Prior Art References

The examination of US11058757 reveals a lengthy list of cited U.S. patents, predominantly by Giebink et al., covering various aspects of pneumococcal conjugate vaccines. For the purpose of this obviousness analysis, we will focus on key representative prior art documents that broadly cover the claimed elements:

• US5623057A (Giebink et al.): This patent describes conjugate vaccines comprising partially hydrolyzed capsular polysaccharide (Ps) from Streptococcus pneumoniae linked to an immunogenic carrier protein. It also explicitly teaches vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein conjugates, which induce broadly protective immune responses against the cognate pathogens. It lists numerous serotypes, including 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F, as potential components.
• WO2015144031A1: This publication discloses a Streptococcus pneumoniae polysaccharide protein conjugated vaccine comprising one or multiple immune conjugates where capsular polysaccharide is coupled with protein. It specifically mentions that the capsular polysaccharide can be isolated from various serotypes including 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. The document further discusses a 7-valent pneumococcal protein vaccine and a 13-valent conjugate vaccine in development by Pfizer.
• WO2007071707A2: This reference provides a multivalent Streptococcus pneumoniae immunogenic composition with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to two or more different carrier proteins.
• "Conjugation Mechanism for Pneumococcal Glycoconjugate Vaccines: Classic and Emerging Methods" (PMC, 2022): This review article discusses the state of the art in S. pneumoniae glycoconjugate vaccines, noting that such vaccines are generally prepared by coupling native or sized polysaccharides to a carrier protein. It highlights the use of CRM197 (a diphtheria toxoid mutant) and other proteins like diphtheria toxoid (DT) and tetanus toxoid (TT) as carrier proteins in existing vaccines such as Prevnar and Synflorix. It also mentions that Avery conjugated pneumococcal polysaccharides to proteins in 1929 to improve immunogenicity.
• "Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses" (PMC, 2022): This article discusses two pneumococcal vaccines in current use: PPSV23 (23-valent polysaccharide vaccine) and PCV13 (13-valent glycoconjugate vaccine). It confirms that PCV13 elicits IgG and OPA titers against various serotypes including 1, 3, 6A, 6B, 7F, 19A, 19F, and 23F, using carrier protein CRM.

Obviousness Arguments

Claim 1: Pharmaceutical Composition

Claim 1 protects a pharmaceutical composition comprising a mixture of at least five distinct saccharide-polypeptide conjugate components, each with a saccharide from a unique Streptococcus pneumoniae serotype, chemically attached to a polypeptide carrier, where the saccharides are not derived from the polypeptide carrier.

Combination of US5623057A and the general knowledge in the art:

US5623057A explicitly teaches a novel conjugate vaccine comprising capsular polysaccharide from Streptococcus pneumoniae linked to an immunogenic carrier protein. It further teaches that vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein conjugates are effective in inducing broadly protective immune responses. The patent lists numerous distinct S. pneumoniae serotypes. This reference directly anticipates or makes obvious the concept of a multi-component vaccine where each component consists of a saccharide from a distinct Streptococcus pneumoniae serotype conjugated to a polypeptide carrier.

A PHOSITA, faced with the goal of creating a vaccine against a broader range of S. pneumoniae serotypes, would have a clear motivation to combine more than one conjugate component from different serotypes, as taught by US5623057A. The selection of at least five distinct serotypes would be a matter of routine optimization, driven by epidemiological data on prevalent serotypes, without requiring undue experimentation. Indeed, the art already practiced vaccines like PCV7 and PCV13, demonstrating the common practice of combining multiple serotypes. The requirement that the saccharides are not derived from the polypeptide carrier is inherent to the definition of a conjugate vaccine where a foreign antigen (saccharide) is linked to a carrier molecule (polypeptide) to enhance immunogenicity. Therefore, a PHOSITA would find it obvious to formulate a pharmaceutical composition containing at least five distinct conjugate components as claimed in Claim 1.

Motivation to combine: The primary motivation would be to broaden the protective efficacy of the vaccine against a wider array of Streptococcus pneumoniae serotypes, a long-standing goal in vaccine development. The art, as exemplified by US5623057A and other references (e.g., WO2015144031A1 and the discussion of PCV13), clearly teaches the benefit of multivalent conjugate vaccines.

Claim 15: Method of Treatment

Claim 15 covers a method for stimulating an immune response in a subject against Streptococcus pneumoniae by administering the pharmaceutical composition of Claim 1.

Combination of US5623057A and general medical knowledge:

US5623057A explicitly states that its conjugate vaccines are "useful in the prevention of pneumococcal infections" and that they "induce broadly protective recipient immune responses." Administering a vaccine to stimulate an immune response is the fundamental purpose and well-known method of use for any vaccine. A PHOSITA, upon developing or obtaining the vaccine composition described in Claim 1 (which itself would be obvious), would find it obvious to administer it to a subject to elicit an immune response against Streptococcus pneumoniae.

Motivation to combine: The motivation to administer the vaccine is self-evident: to protect subjects from Streptococcus pneumoniae infections. This is the intended purpose of vaccine development and a routine clinical step known to any PHOSITA.

Claim 16: Manufacturing Method

Claim 16 outlines a manufacturing method for the pharmaceutical composition, involving combining at least five separate conjugate components, each featuring a saccharide from a different Streptococcus pneumoniae serotype covalently linked to a polypeptide, where the saccharides are not derived from the polypeptide.

Combination of US5623057A, WO2015144031A1, and common knowledge in pharmaceutical manufacturing:

US5623057A describes the production of conjugate vaccines and mentions mixtures of such conjugates. WO2015144031A1 further details the separation and purification of capsular polysaccharides and carrier proteins, and the coupling methods for preparing pneumococcal protein vaccines. The reference also mentions the selection of multiple serotypes for vaccine preparation, such as 24 serotypes for purification.

A PHOSITA would know that creating a multi-component vaccine involves preparing each conjugate component individually and then combining them to form the final vaccine composition. The manufacturing process of "combining at least five separate conjugate components" is a straightforward and conventional step in formulating multivalent vaccines. This is explicitly taught by the prior art, which discusses multi-valent pneumococcal vaccines. The methods for isolating polysaccharides and coupling them to carrier proteins are also described as "prior art which has been mastered by a person skilled in the art."

Motivation to combine: The motivation for combining individually prepared conjugate components is to create a single, administrable multi-valent vaccine product that provides broad protection against multiple serotypes, which is a desirable and known outcome in vaccine manufacturing. The process of combining different components to achieve a desired multi-valent formulation is standard practice in pharmaceutical composition, requiring no inventive step.

Conclusion on Obviousness

The independent claims of US patent 11058757 appear to be obvious under 35 U.S.C. § 103 in light of the cited prior art. The concept of creating multi-component saccharide-polypeptide conjugate vaccines against Streptococcus pneumoniae using distinct serotypes, methods of administering such vaccines to stimulate an immune response, and the manufacturing process of combining these components were all well-established in the art prior to the priority date of US11058757. Specifically, US5623057A and other contemporary references clearly disclose the core elements of the claims, and a PHOSITA would have been motivated to combine these teachings to create the claimed invention for the evident benefit of broader protective immunity. Further, the method claims and manufacturing claims rely on the obviousness of the composition and standard industry practices.